From FDA to MHRA: are drug regulators for hire?

January 25, 2023January 25, 2023 Ms. Cat

Patients and doctors expect drug regulators to provide an unbiased, rigorous assessment of investigational medicines before they hit the market. But do they have sufficient independence from the companies they are meant to regulate? Maryanne Demasi investigates
From FDA to MHRA: are drug regulators for hire?

This is probably the worst thing I have seen so far.

May 28, 2022May 28, 2022 Ms. Cat

You can’t spell hypocrisy without psycho!
Unacceptable Jessica May 28, 2022
Please read this article recently published online in the Toronto Star and written by Health Reporter Megan Ogilvie and Staff Reporter May Warren. You can simply read my screenshots if you’ve been subjected to inflation. To summarize, one Torontonian Dr. Sun claims to have put HIS neck on the line by illegally and unethically injecting 500 infants (children <5) with COVID-19 products that are now proven entirely obsolete against Omicron, in order to protect them from Omicron. Sounds informed and up-to-date, doesn’t he?
This is probably the worst thing I have seen so far.

H/T: Unorthodox Truth

Covid-19 vaccines and treatments: we must have raw data, now

January 25, 2022January 25, 2022 Ms. Cat

Covid-19 vaccines and treatments: we must have raw data, now

H/T:

PFYT2 Truth Exists: Lies Are Made Up

Vaccines are a tool, not a silver bullet. If we’d allowed more scientific debate, we would have realized this earlier

January 25, 2022January 25, 2022 Ms. Cat

Vaccines are a tool, not a silver bullet. If we’d allowed more scientific debate, we would have realized this earlier

Penny’s Commentary:

Part 1

Part 2

Part 3

Why Is the Gates Foundation Funding the UK’s Medicines Regulator?

August 28, 2021August 28, 2021 Ms. Cat

Why Is the Gates Foundation Funding the UK’s Medicines Regulator?

“Safety in a world of user fees” is of paramount concern, concluded Lexchin. That was was back in 2017. Four years on, we are in the biggest health crisis of our lifetimes and the tasks performed by medicines regulators are more important than ever. New experimental vaccines and therapeutic treatments are rolling off the line in record time. But they’re also being authorised in record time — in some cases despite scant evidence of benefits (e.g., Remdesivir). And they’re earning record profits for their manufacturers. At the same time, promising repurposed off-patent medicines that do not offer lucrative financial returns are largely being ignored or are even being demonised by our medicines regulators.